Search results for: ""

Positive Two-Year Data from MiStent® DESSOLVE III Trial Presented at EuroPCR – Excellent safety and low target lesion revascularization (TLR) rates persist –

Durham, NC – May 23, 2018 — A 24-month update on the DESSOLVE III trial of the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) was presented this week at EuroPCR 2018, an international congress of interventional cardiovascular medicine researchers and clinicians held in Paris, France. Data were presented by William Wijns, M.D., Ph.D., of […]

Read more...

Micell Technologies Announces Expanded Patent Estate – Issued Key Patents Significantly Strengthen Company’s Proprietary Rights in Surface Modification and Controlled Drug Delivery

Durham, NC – March 20, 2018 — Micell® Technologies, Inc., a privately-held, development-stage biomedical company, today provided an update on its recently expanded intellectual property portfolio. With the granting of 24 patents in 2017, including eight that issued in the fourth quarter, Micell’s extensive intellectual property portfolio comprises 186 patents (166 issued and 20 allowed) protecting the […]

Read more...

Study Validates New Approach for Optimizing Endovascular Drug Delivery Using Stents with a Deployable Coating That Enhances Sirolimus Distribution Compared to Traditional DES

“This preclinical demonstration that stent deployment of microcrystalline drug in combination with a rapidly absorbable polymer, such as with MiStent, results in more uniform drug dosing that could lead to more rapid and uniform healing across the treated segment,” said David Kandzari, M.D., Director of Interventional Cardiology and Chief Scientific Officer, Piedmont Heart Institute, Atlanta. LEXINGTON, Mass.- […]

Read more...

Positive Five-Year Data Published for MiStent in EuroIntervention Results continue to show excellent long-term safety and effectiveness

Durham, NC – January 9, 2018 — Micell Technologies, Inc. announced the recent online publication of five-year data from the DESSOLVE I and II trials. The report, “Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials” was peer reviewed and […]

Read more...

The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All-Comers Randomized Trial – MiStent Achieved Primary Endpoint vs Xience® –

Durham, NC – December 6, 2017 — Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex patient population for the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) versus the Xience® Everolimus Eluting Coronary Stent System […]

Read more...

Micell Technologies Announces MiStent Achieved Primary Endpoint in All-Comers Randomized Clinical Trial Versus Xience; MiStent Data the Subject of Three EuroPCR 2017 Presentations

Paris, France – May 16, 2017 — Micell Technologies announced today at the late-breaking trial session of EuroPCR – the official congress of the European Association of Percutaneous Cardiovascular Interventions – positive twelve-month data from its DESSOLVE III clinical trial. The study met its primary endpoint, showing non-inferior safety and effectiveness outcomes in a complex […]

Read more...

Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial of MiStent In Japan

DURHAM, N.C., November 28, 2016 — Micell Technologies, Inc. (Micell) announced enrollment of the first patient in DESSOLVE J: a prospective, randomized, balanced, controlled, double-blind, multi-center study comparing MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent) to XIENCE V Everolimus Eluting Coronary Stent System (Xience) in Japan. Shigeru Saito, M.D., Vice Director, Shonan […]

Read more...

Positive Five-Year Clinical Data from Micell Technologies’ MiStent Presented at TCT 2016

DURHAM, N.C., October 31, 2016 — Micell Technologies, Inc. (Micell) today announced that it presented five-year clinical safety and efficacy results from the DESSOLVE I and II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent®). MiStent is designed to optimize vessel healing and long-term clinical performance in patients with coronary artery […]

Read more...

Patents

Read more...

Propensity Analysis vs. Xience

Read more...

DESSOLVE China Three-Year Angiographic Sub-study

Read more...

DESSOLVE China

Read more...

DESSOLVE III OCT Sub-study

Read more...

DESSOLVE III Clinical Trial

Read more...

DESSOLVE II Clinical Trial

Read more...

DESSOLVE I Clinical Trial

Read more...

Dr. Dean Kereiakes

Dean Kereiakes, M.D. Medical Director, The Christ Hospital Heart and Vascular Center Medical Director, Carl and Edyth Lindner Center for Research and Education, The Christ Hospital Chief Executive Officer & Director, Medical Research, The Ohio Heart Health Center Chairman, Executive Committee & Founder, The Ohio Heart & Vascular Center Professor, Clinical Medicine, Ohio State University […]

Read more...

Archived Releases

Read more...

Copyright

Micell, MiStent, and MiStent SES are registered trademarks of Micell Technologies, Inc. Caution: The MiStent SES has received CE marking but is not approved in the USA or any other countries. Any other products described on this website are investigational devices that are not available for sale in any country.

Read more...

William Wijns

William Wijns, M.D., Ph.D. Principal Investiga, for Micell’s DESSOLVE I and DESSOLVE II Clinical Trials Co-Director, Cardiovascular Center, Aalst, Belgium William Wijns, M.D., Ph.D. graduated in 1976 from the University of Louvain, Belgium where he trained as a cardiologist until 1981. He has served as Co-Director of the Cardiovascular Center in Aalst, Belgium since 1994. […]

Read more...

Patrick Serruys

Patrick Serruys, M.D., Ph.D. Chief of Interventional Cardiology, Thoraxcenter-Erasmus University, Rotterdam, The Netherlands Co-Founder and Board Member of EuroPCR, Paris, France Patrick Serruys, M.D., Ph.D. is a professor at Erasmus University Medical Center, Rotterdam, The Netherlands and served as Professor of Interventional Cardiology at the Interuniversity Cardiological Institute of The Netherlands from 1988 to 1998. […]

Read more...

Martin B. Leon

Martin B. Leon, M.D. Founder and Chairman Emeritus, Cardiovascular Research Foundation Professor of Medicine, Columbia University College of Physicians and Surgeons Associate Director, Center for Interventional Vascular Therapy, New York-Presbyterian Hospital/Columbia University Medical Center Martin B. Leon, M.D. serves as a Professor of Medicine at Columbia University Medical Center and is the Chairman Emeritus, President […]

Read more...

Peter J. Fitzgerald

Peter J. Fitzgerald, M.D., Ph.D. Professor of Medicine & Engineering, Stanford University Medical Center Director, Interventional Cardiology Research Lab, Stanford Medical School Director, Center for Cardiovascular Technology, Stanford University Director, Cardiovascular Core Analysis Laboratory, Stanford Medical School Entrepreneur Peter J. Fitzgerald, M.D., Ph.D. is an interventional cardiologist and holds a PhD in biomedical engineering. He […]

Read more...

David E. Kandzari

<strong>David E. Kandzari, M.D.</strong> <em>Director, Interventional Cardiology and Research, Piedmont Heart Institute Former CMO, Johnson &amp; Johnson’s Cordis Cardiology Unit Former Medical Officer, FDA’s Center for Devices and Radiological Health</em> David E. Kandzari, M.D. earned his undergraduate degree from Duke University School of Medicine and completed his internship and residency at The John Hopkins University […]

Read more...

Elazer R. Edelman

Elazer R. Edelman, M.D., Ph.D. Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology, MIT Attending Cardiologist, Brigham and Women’s Hospital Director, Harvard – MIT Biomedical Engineering Center (BMEC) Elazer R. Edelman, M.D., Ph.D., is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at MIT, Professor of […]

Read more...

Renu Virmani

Renu Virmani, M.D., F.A.C.C. Founder, President and Medical Director, CVPath Institute Clinical Professor, Department of Pathology at Georgetown University, University of Maryland-Baltimore, George Washington University and Vanderbilt University Former Chairperson, Department of Cardiovascular Pathology, Armed Forces Institute of Pathology Renu Virmani, M.D., F.A.C.C. is an internationally renowned cardiovascular pathologist who is recognized as a leading […]

Read more...

Kenneth Rosenfield

Kenneth Rosenfield, M.D. Director, Cardiac & Vascular Invasive Services, Massachusetts General Hospital Kenneth Rosenfield, M.D. is Head of the Section of Vascular Medicine and Intervention in the Division of Cardiology at Massachusetts General Hospital. His research focuses on novel, minimally invasive strategies for treating complex peripheral and coronary artery disease. Dr. Rosenfield is a leader […]

Read more...

Stanley Katz

Stanley Katz, M.D. Chairman, Department of Cardiology, and Senior Vice President, Cardiovascular Services, North Shore-Long Island Jewish Health System Stanley Katz, M.D. serves as Senior Vice President of Cardiovascular Services, Chairman of Cardiology LIJ Medical Center and Chairman of Cardiology, North Shore University Hospital. He also oversees New York’s largest cardiac catheterization laboratory at NSUH, […]

Read more...

Michael R. Jaff

Michael Jaff, D.O. Medical Director, Massachusetts General Hospital Vascular Center Founder and Medical Director, VasCore, The Vascular Ultrasound Core Laboratory Medical Director, Center for Specialized Services Michael R. Jaff, D.O. is Professor of Medicine at Harvard Medical School; Medical Director of the Fireman Vascular Center; and Medical Director of the Massachusetts General Hospital, Center for […]

Read more...

Robert Glickman

Robert Glickman, M.D. Former Dean, New York University School of Medicine Former CEO, NYU Hospital Center, NYU Langone Medical Center Robert M. and Mary H. Glickman Professor of Medicine and Gastroenterology, New York University School of Medicine Robert M. Glickman, M.D. has served as Dean of New York University School of Medicine and Chief Executive […]

Read more...

Robert Langer

Robert Langer, Ph.D., Sc.D. Chairman, Micell Scientific Advisory Board Institute Professor, Massachusetts Institute of Technology Robert S. Langer, Ph.D., Sc.D. is the David H. Koch Institute Professor at Massachusetts Institute of Technology. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995-2002 and […]

Read more...

Michael Stansky

Michael Stansky Former Managing Director, Tudor Investment Corporation Michael Stansky, CFA served as a Managing Director at Tudor Investment Corporation and as a Managing Director at Tudor Growth Equity. He joined Tudor Investment in January 1994 and retired from active investment management on December 31, 2008. Mr. Stansky also served as an Independent Director at […]

Read more...

John Lowry

John Lowry President & Chief Executive Officer, Amerigen Pharmaceuticals, Inc. John Lowry was appointed President & CEO of Amerigen in 2010. Mr. Lowry has nearly 30 years of experience, most of which is in leading product development organizations and global businesses in the pharmaceutical and medical device industries. Most recently, Mr. Lowry was CEO of […]

Read more...

Kenneth G. Langone

Kenneth G. Langone Founder, Chairman & Chief Executive Officer, Invemed Associates LCC Co-Founder, Home Depot, Inc. Kenneth G. Langone is the Founder and Chief Executive Officer of Invemed Associates LLC, a New York Stock Exchange member firm specializing in healthcare and high technology companies. He is a Co-Founder of Home Depot, Inc., and was a […]

Read more...

Dr. Robert Langer

Robert S. Langer, Ph.D., Sc.D. Chairman, Micell Scientific Advisory Board Institute Professor, Massachusetts Institute of Technology Robert S. Langer, Ph.D., Sc.D. is the David H. Koch Institute Professor at Massachusetts Institute of Technology. He served as a member of the United States Food and Drug Administration’s SCIENCE Board, the FDA’s highest advisory board, from 1995-2002 […]

Read more...

Arthur J. Benvenuto

Read more...

Donald H. Hamilton, P.E.

Donald H. Hamilton, P.E. Manufacturing Advisor Don is a technical leader with international product development and manufacturing experience across multiple industries. He has about 30 years industry experience with medical disposables, medical devices and combination drug/device products. Prior to working with Micell, Don was with Johnson & Johnson for a total of 14 years. He […]

Read more...

Jack Springer

Jack Springer Business Development and Commercialization Advisor Jack has spent the last 25+ years in medical devices and diagnostics. He is currently a board member and consultant to several cardiovascular device companies. Jack spent most of his career in sales and marketing roles as well as executive management positions within the medical device field including […]

Read more...

Dennis J. Donohoe

Dennis J. Donohoe, M.D. Chief Medical Advisor Dennis is a primary care physician who practiced in the Philadelphia area for five years before joining the industry. He has about 26 years of industry experience in both pharmaceutical and medical/surgical device clinical development. Prior to working with Micell, Dennis worked in various Johnson & Johnson capacities […]

Read more...

Tim Kiorpes

Tim Kiorpes, Ph.D. Chief Technology Advisor Tim serves as Chief Technology Advisor with responsibility for Product Development, Preclinical Testing, Analytical Chemistry, and Intellectual Property. He has worked with Micell since early 2010 and assumed his current role in 2015. Previously, Tim was with Johnson & Johnson (J&J) for over 26 years and is broadly experienced […]

Read more...

Arthur J. Benvenuto

Arthur J. Benvenuto Chairman and Chief Executive Officer Art serves as Chairman and Chief Executive Officer, a position he has held since leading the formation of Micell’s biomedical business in 2006. Prior to being named to his current role, Art served as Chairman, Life Sciences for RA Capital Group, an advisor to venture capital firms, […]

Read more...

Product Pipeline

Read more...

Health Economics

Health Economics Lower TLR rates can have a significant impact on reducing cost to the healthcare system. A 50 percent reduction in TLR would translate into meaningful savings for hospitals, insurers and patients. Cost Impact of TLR Reduction Average Medicare, in-patient hospital reimbursement for percutaneous vascularization with a DES* $11,800 without complications (Diagnosis Related Group […]

Read more...

MiStent

Read more...

Media Resource Center

Read more...

Presentations

PRESENTATIONS Clinicians and academics regularly present key data updates to the interventional cardiology community.  See below for a representative list of recent presentations, and click on the society link to see them. (Note some societies require membership to access presentations.) EuroPCR 2017 How a unique DES platform translates into clinical differentiation with MiStent: from premise […]

Read more...

Publications

Publications A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Robbert J. de Winter, Yuki Katagiri, Taku Asano, Krzysztof P. Milewski, Philipp Lurz, Pawel Buszman, Gillian A.J. Jessurun, Karel T. Koch, Roland P.T. Troquay, Bas J.B. Hamer, […]

Read more...

Search result

Read more...

Micell Technologies Completes Enrollment in OCT Study Designed to Evaluate Superior Performance of MiStent SES Compared to Xience

DURHAM, N.C., March 22, 2016 — Micell Technologies, Inc. announced completion of enrollment in the MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) Optical Coherence Tomography (OCT) study. The study will compare changes in coronary arteries between six and 24 months following treatment with MiStent or XIENCE V Everolimus Eluting Coronary Stent System […]

Read more...

News

Welcome to Micell’s news section. We welcome inquiries from the media and have designed this section to give you access to timely and relevant information about our Company. Here, you will find press releases and publications, relevant fact sheets and statistics, and a collection of images and videos in our resource center. For more detailed […]

Read more...

Terms & conditions

TERMS OF USE Welcome to the Micell Technologies, Inc. (“Micell”) website at www.www.micell.com (or successor URLs) (collectively, the “Site”). The following Terms of Use for the Site is a legal contract between you, either an individual visitor or user of at least 18 years of age, and Micell regarding your use of the Site. Visitors […]

Read more...

Privacy

Privacy Policy Micell values your privacy and the privacy of our other customers and visitors of the Site (referred to individually as “User” and collectively as “Users”). This Privacy Policy describes what information we gather from you, how we use that information, and what we do to protect it. By using the Site, you expressly […]

Read more...

Sitemap

Sitemap Homepage Technology Products MiStent SES Health Economics Product Pipeline Clinical Trials Preclinical Studies DESSOLVE I Study DESSOLVE II Study DESSOLVE III Study DESSOLVE III OCT Sub-study DESSOLVE China DESSOLVE China Three Year Angiographic Sub-study Propensity Analysis vs Xience News Press Releases Archived Releases Publications About Executive Leadership Board of Directors Scientific Advisory Board Scientific […]

Read more...

Contact

Read more...

Health Economics

Read more...

Clinical Trials

Read more...

Preclinical Studies

Read more...

CLINICAL TRIALS

Read more...

PRODUCTS

Read more...

TECHNOLOGY

Read more...

Scientific Advisors

Read more...

Scientific Advisory Board

Read more...

Board of Directors

Read more...

Executive Leadership

Read more...

About Micell

Read more...

About

Micell Technologies is an innovative technology company dedicated to transforming medical devices for improved patient outcomes. The Company’s supercritical fluid technology is a key component in its enhanced drug delivery system, which is currently in use within the interventional cardiology market, though the technology has potentially far-reaching applications for treating cardiovascular disease. Focused on eliminating […]

Read more...

Home page

Read more...

Micell Technologies Highlights Data From Published Propensity Analysis of MiStent SES® and Market Standard Xience V® Coronary Stent

— Publication in American Journal of Cardiology Demonstrates Reduced Target Lesion Revascularization Rates at One and Three Years Post-Treatment Compared to Durable Polymer Everolimus-Eluting Stent — DURHAM, N.C., February 25, 2016 — Micell Technologies, Inc. announced that data have been published from a retrospective cross-study propensity analysis comparing MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent […]

Read more...

Micell Technologies Announces Completion of Enrollment in MiStent Randomized Trial against Xience

• DESSOLVE III clinical trial enrolled 1,400 “all-comers” patients • Primary endpoint results to be announced in H1 2017 DURHAM, N.C., December 9, 2015 — Micell Technologies, Inc. announced the completion of patient enrollment in DESSOLVE III, a 1,400 patient, 20 center, randomized clinical trial comparing MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent […]

Read more...

Positive Four-Year Clinical Data from Micell Technologies’ MiStent SES Presented at TCT 2015

DURHAM, N.C., October 13, 2015 — Micell Technologies, Inc. today announced four- year clinical results from the DESSOLVE I and II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 27th Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference held in San Francisco, October 11-15. TCT is the world’s […]

Read more...

Micell Technologies Announces Surgical Technologies Approved as MiStent SES Commercial Manufacturer for CE Mark Countries

DURHAM, N.C., August 20, 2015 — Micell Technologies, Inc. announced that its application for a manufacturing partner, Surgical Technologies, Inc. (STI), was approved by British Standards Institution (BSI) to begin full-scale manufacturing of Micell’s MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System for commercial distribution in the European Union and other countries where the […]

Read more...

Micell Technologies Announces First Patient Enrolled in Registration Trial of MiStent SES in China

DURHAM, N.C., July 22, 2015 — Micell Technologies, Inc. has begun enrolling patients in DESSOLVE C: a prospective, single-blind, multi-center, randomized, controlled clinical trial to demonstrate the efficacy and safety of its MiStent SES® Sirolimus Eluting Absorbable Polymer Coronary Stent System. MiStent SES is used to treat patients with coronary artery disease, and its performance […]

Read more...

EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post- Treatment

Paris, France – May 19, 2015 — At the late-breaking trials session today at EuroPCR, the official congress of European Association of Percutaneous Cardiovascular Interventions, data from a retrospective cross-study propensity analysis were presented comparing MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) to XIENCE V Everolimus Eluting Coronary Stent System (Xience). These […]

Read more...

Micell Technologies: First Patient Enrolled in All-comers Randomized Trial of MiStent Against Xience

DURHAM, N.C., March 23, 2015 — Micell Technologies, Inc. announced it has begun patient enrollment in DESSOLVE III, a randomized, controlled clinical trial comparing MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System to XIENCE Everolimus Eluting Coronary Stent System® (Xience®). Robbert J. de Winter, M.D., Ph.D., Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands […]

Read more...

Micell Technologies’ MiStent SES® Now Commercially Available in Europe

— Novel Drug-delivery Technology Provides Sirolimus-Eluting Stent with Unique Bioabsorbable Polymer Absorption and Drug Release Profile — DURHAM, N.C. – Feb. 4, 2015 – Micell Technologies, Inc., a biomedical company that is enhancing the performance of cardiovascular medical devices with innovative drug-delivery systems, today announced the commercial availability of the MiStent® Sirolimus Eluting Absorbable Polymer […]

Read more...

Micell Technologies Announces Plans for MiStent SES® Commercial Launch

— Distribution Agreement Secured with STENTYS — DURHAM, N.C., November 3, 2014 — Micell Technologies, Inc. today announced commercialization plans for its MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®). In support of this strategy, the company has entered into a five-year agreement with STENTYS (Princeton, NJ and Paris, France) as an exclusive […]

Read more...

Micell Technologies Highlights Positive Three-Year Data from MiStent SES DESSOLVE Clinical Studies at TCT 2014

— Differentiated Design Yields Excellent Tissue Healing and Sustained Safety Profile — DURHAM, N.C., September 16, 2014 — Micell Technologies, Inc. today announced that three- year clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) were presented at the 26th Annual Transcatheter […]

Read more...

Micell Technologies Adds to Portfolio of Intellectual Property Protection

— Newly Issued US Patent Covers Medical Device Coating Process and Compositions — DURHAM, N.C., July 9, 2014 — Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent related to Micell’s technology for enhancing the performance of medical devices with precise drug-delivery coatings. These technologies currently […]

Read more...

Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014

— Sustained Safety Profile – DURHAM, N.C., May 23, 2014 — Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. Presentations by principal investigator William Wijns, M.D., Ph.D. of the Cardiovascular Center in Aalst, Belgium, highlighted […]

Read more...

Micell Technologies Announces Clinical Data from MiStent SES Studies Will Be Presented at EuroPCR 2014

— Oral Presentations to Include New Long-Term Results from First-in-Human Study — DURHAM, N.C., May 15, 2014 — Micell Technologies, Inc. today announced the updated three- and two-year clinical outcomes from its DESSOLVE I and II clinical trials, respectively, will be presented at the EuroPCR conference to be held in Paris, France from May 20 […]

Read more...

Long-Term Safety and Efficacy of MiStent SES Presented at CRT 2014

— Rapid polymer absorption within three months coupled with drug — delivery profile up to nine months provides for excellent healing DURHAM, N.C., March 5, 2014 — Micell Technologies, Inc. today announced that the long-term clinical outcomes from the DESSOLVE I and II clinical trials recently were presented at the Cardiovascular Research Technologies (CRT) Conference […]

Read more...

Paper Published in American Journal of Cardiology Demonstrates Favorable Vascular Healing Following MiStent SES Implantation

– Notably Lower Rates of Neoatherosclerosis Reported Following MiStent SES® Implantation Versus Other Drug Eluting Stents – DURHAM, N.C., November 21, 2013 — Micell Technologies, Inc. today announced that The American Journal of Cardiology® published results of a comprehensive analysis of optical coherence tomography (OCT) following MiStent SES implantation. Evaluations of vascular healing taken at […]

Read more...

MiStent SES Shown to be Unique in Clinical Setting

– Demonstrated Lack of Late Lumen Loss Progression Over 18 Months in Conjunction with Excellent Tissue Healing – Two-Year Clinical Data Presented at TCT 2013 DURHAM, N.C., October 28, 2013 — Micell Technologies, Inc. today announced that imaging and clinical results from the DESSOLVE I and DESSOLVE II trials of its MiStent Sirolimus Eluting Absorbable […]

Read more...

Micell Technologies Announces Development and Distribution Agreement to Bring MiStent SES to China

— Hefei Life Science will fund and manage clinical development and distribution — DURHAM, N.C., October 1, 2013 — Micell Technologies, Inc. has entered into an agreement with Hefei Life Science Technology Park Investment and Development Co., Ltd. (Hefei Life Science), for the clinical development, marketing and distribution of the MiStent Sirolimus Eluting Absorbable Polymer Coronary […]

Read more...

Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiology’s Cardiovascular Interventions Journal

— TCT 2013 presentation of data planned — DURHAM, N.C., September 30, 2013 — Micell Technologies, Inc. today announced that a peer reviewed article discussing imaging and clinical results of the DESSOLVE I trial of its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) was accepted for publication on the JACC Cardiovascular Interventions […]

Read more...

Micell Technologies Receives CE Mark Approval for MiStent SES

— Unique safety profile could benefit patients with coronary artery disease — DURHAM, N.C., June 12, 2013 — Micell Technologies, Inc. received CE (Conformité Européenne) Mark approval for its MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) introducing a thin-strut stent that features elimination of the coating from the stent in 45-60 days […]

Read more...

Micell Technologies Announces Issuance of Core Technology Patent

DURHAM, N.C., November 6, 2012 — Micell Technologies, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the company’s surface and polymer modification technology. This intellectual property protection is related to Micell’s investigational MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SESTM), as well as potential […]

Read more...

Micell Technologies Announces Positive Data from Clinical Studies of MiStent SES

— Presented at TCT 2012 — — Minimal Progression of Late Lumen Loss through 18 Months — — Superior Performance Against Primary Endpoint — DURHAM, N.C., October 23, 2012 — Micell Technologies, Inc. today announced positive data from two clinical studies of its investigational MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SESTM), a […]

Read more...

Micell Technologies Announces Clinical Data Presentations at TCT 2012

DURHAM, N.C., October 16, 2012 — Micell Technologies, Inc. today announced that data from clinical studies of its investigational MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SESTM) will be presented at the 24th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium to be held in Miami, Fla. on October 22 – 26, 2012. David […]

Read more...

Micell Technologies Announces Positive Preliminary Data from DESSOLVE I Study of MiStent® Sirolimus Drug Eluting Coronary Stent System

DURHAM, N.C., November 8, 2011 — Micell Technologies, Inc. today announced the release of preliminary data from the first-in-human clinical study of the MiStent® Sirolimus Drug Eluting Coronary Stent System (MiStent DES), a thin-strut drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating designed for controlled drug release. Four, six and eight month data from the […]

Read more...

Micell Technologies Announces Presentation of Clinical Data at TCT 2011

DURHAM, N.C., November 2, 2011 — Micell Technologies, Inc. today announced that it has completed a preliminary analysis of data from the first-in-human clinical study, DESSOLVE I, of the MiStent® Sirolimus Drug Eluting Coronary Stent System, a thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation that is designed for controlled drug release. Four, […]

Read more...

Micell Technologies Completes Enrollment in DESSOLVE II Study of the MiStent® Drug-Eluting Coronary Stent

DURHAM, N.C., July 26, 2011 — Micell Technologies, Inc. today announced that it has completed patient enrollment in its DESSOLVE II CE Mark clinical study of the MiStent® Drug-Eluting Coronary Stent System. The MiStent DES is an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Enrollment of 183 patients across 26 study centers […]

Read more...

Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug- Eluting Coronary Stent Based on Early Clinical Data

DURHAM, N.C., June 29, 2011 — Micell Technologies, Inc. today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent Drug-Eluting Coronary Stent System (“MiStent DES”), an ultra-thin drug-eluting stent distinguished by a rapid-absorbing drug/polymer coating formulation. Based on […]

Read more...

Micell Technologies Reports Preclinical Data for MiStentTM Drug-Eluting Coronary Stent to be Presented at EuroPCR

 – Consistent and Controlled Drug Delivery from a Rapidly Absorbable Coating – DURHAM, N.C., May 11, 2011 — Micell Technologies, Inc. today announced that positive preclinical data will be presented at the EuroPCR conference in Paris, France on May 18, 2011 in a presentation titled, “MiStent DES: A Novel Third Generation DES with a Fully-absorbable […]

Read more...

Micell Technologies Enrolls First Patient in CE Mark DESSOLVE II Study of MiStentTM Drug-Eluting Coronary Stent (DES)

  MiStent DES is a drug-eluting stent designed to optimize healing   Dissolution kinetics of drug and polymer converts MiStent DES into a bare-metalstent within 45 to 60 days   MiStent DES has the potential to uniquely combine safety and efficacy with excellentdeliverability DURHAM, N.C., February 17, 2011– Micell Technologies,TM Inc. today announced it has […]

Read more...

Micell Technologies Enrolls First Patient in DESSOLVE I First-In-Human Study of MiStent DES

MiStent DES Delivers Sirolimus via Bioabsorbable Polymer; Drug and Polymer are Designed to be Eliminated within 90 days with Optimized Dissolution Kinetics DURHAM, N.C., November 29, 2010– Micell Technologies,TM Inc. today announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer […]

Read more...

Micell Receives $15 Million Equity Investment

RALEIGH, NC, September 21, 2009 ‐ Micell Technologies announced today that St. Jude Medical, Inc. has made a $15 million equity investment in the company. Arthur J. Benvenuto, chairman and chief executive officer of Micell, said, “We are excited to have a company of St. Jude Medical’s stature make an investment in Micell. We look […]

Read more...

Micell Technologies’ Rapid Absorption Polymer DES System to be Presented at CRT 2009

RALEIGH, N.C., March 4, 2009 /PRNewswire/ — Micell Technologies announced today that David E. Kandzari, MD, will present “The Micell Rapid Absorption Polymer DES System” during the Cardiovascular Research Technologies (CRT) meeting in Washington, DC, on March 5, 2009. MiStentTM, a Drug-Eluting Stent (DES) in pre-clinical studies, utilizes a bioabsorbable polymer coating that delivers the […]

Read more...

Micell Forges Strategic Agreement to Develop Advanced Drug-Eluting Stents and Balloons

Company In-licenses State-of-the-art CE-Marked Cobalt-Chromium Coronary Stent Forms Alliance to Jointly Develop Drug Eluting Balloon Products RALEIGH, NC, January 12, 2009 – Micell Technologies announced today that that the company entered into a strategic agreement with Maxcor Inc., the newly incorporated subsidiary of Opto Circuits (OCI) Ltd., by which Micell Technologies has obtained the rights […]

Read more...